Sumitomo Mitsui Trust Group
ARCT icon

Sumitomo Mitsui Trust Group’s Arcturus Therapeutics ARCT Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$23.1M Sell
1,689,107
-274,016
-14% -$2.86M 0.01% 583
2026
Q2 		$13.2M Sell
1,963,123
-325,812
-14% -$2.57M 0.01% 650
2026
Q1 		$17.7M Buy
2,288,935
+262,347
+13% +$1.91M 0.01% 630
2025
Q4 		$12.4M Buy
2,026,588
+78,753
+4% +$851K 0.01% 664
2025
Q3 		$35.9M Buy
1,947,835
+115,368
+6% +$1.85M 0.02% 559
2025
Q2 		$23.8M Sell
1,832,467
-93,617
-5% -$1.11M 0.01% 617
2025
Q1 		$20.4M Sell
1,926,084
-138,966
-7% -$2.21M 0.01% 637
2024
Q4 		$35M Sell
2,065,050
-210,665
-9% -$3.97M 0.02% 541
2024
Q3 		$52.8M Buy
2,275,715
+712,650
+46% +$15.2M 0.04% 436
2024
Q2 		$38.1M Buy
1,563,065
+286,546
+22% +$8.69M 0.03% 498
2024
Q1 		$43.1M Sell
1,276,519
-44,133
-3% -$1.56M 0.03% 534
2023
Q4 		$41.6M Sell
1,320,652
-67,922
-5% -$1.61M 0.03% 528
2023
Q3 		$35.5M Sell
1,388,574
-16,358
-1% -$504K 0.03% 551
2023
Q2 		$40.3M Sell
1,404,932
-16,393
-1% -$446K 0.03% 533
2023
Q1 		$34.1M Sell
1,421,325
-27,735
-2% -$498K 0.03% 597
2022
Q4 		$24.6M Sell
1,449,060
-10,355
-0.7% -$181K 0.02% 667
2022
Q3 		$21.6M Buy
1,459,415
+23,221
+2% +$390K 0.02% 688
2022
Q2 		$22.6M Buy
1,436,194
+34,116
+2% +$669K 0.02% 696
2022
Q1 		$37.8M Buy
1,402,078
+44,606
+3% +$1.14M 0.03% 612
2021
Q4 		$50.2M Sell
1,357,472
-1,060
-0.1% -$43.2K 0.03% 534
2021
Q3 		$64.9M Buy
1,358,532
+143,631
+12% +$6.44M 0.04% 465
2021
Q2 		$41.1M Buy
1,214,901
+899,089
+285% +$30.4M 0.02% 598
2021
Q1 		$13M Buy
315,812
+181,208
+135% +$10.8M 0.01% 756
2020
Q4 		$5.84M Buy
134,604
+3,434
+3% +$233K ﹤0.01% 826
2020
Q3 		$5.63M Sell
131,170
-15,182
-10% -$754K ﹤0.01% 812
2020
Q2 		$6.84M Sell
146,352
-108,714
-43% -$3.75M ﹤0.01% 779
2020
Q1 		$3.47M Sell
255,066
-25,482
-9% -$326K ﹤0.01% 816
2019
Q4 		$3.05M Sell
280,548
-17,982
-6% -$188K ﹤0.01% 857
2019
Q3 		$3.07M Buy
298,530
+168,556
+130% +$1.82M ﹤0.01% 833
2019
Q2 		$1.23M Buy
+129,974
New +$954K ﹤0.01% 880

Other funds holding ARCT

Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Green Alpha Advisors
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
MGO One Seven
MGO One Seven Beachwood, Ohio $6.08B AUM 21.44% 1-Year Est. Return
Apollon Wealth Management
Apollon Wealth Management Mount Pleasant, South Carolina $8.72B AUM 23.07% 1-Year Est. Return
Diversify Advisory Services
Diversify Advisory Services Sandy, Utah $6.69B AUM 18.85% 1-Year Est. Return
Diversify Wealth Management
Diversify Wealth Management Sandy, Utah $6.69B AUM 22.4% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Sumitomo Mitsui Trust Group's ARCT Position: Q3 2026 in Review

Sumitomo Mitsui Trust Group reduced its Arcturus Therapeutics (ARCT) stake by 14% in Q3 2026, selling an estimated $2.86M and leaving 1,689,107 shares worth $23.1M. The position accounts for 0.01% of the portfolio, ranked #583.

Sumitomo Mitsui Trust Group first reported a position in ARCT in Q2 2019 and has held it in 30 quarters since. The position peaked at $64.9M in Q3 2021. 34 funds tracked by Wall St. Rank hold ARCT as of Q3 2026.

  • Sumitomo Mitsui Trust Group held 1,689,107 shares of Arcturus Therapeutics worth $23.1M as of Q3 2026.
  • Sumitomo Mitsui Trust Group sold 274,016 Arcturus Therapeutics shares in Q3 2026, an estimated $2.86M.
  • Arcturus Therapeutics made up 0.01% of Sumitomo Mitsui Trust Group's portfolio in Q3 2026, its #583 holding.
  • Sumitomo Mitsui Trust Group first reported a position in Arcturus Therapeutics in Q2 2019 and has held it in 30 quarters since.
  • Sumitomo Mitsui Trust Group's Arcturus Therapeutics position peaked at $64.9M in Q3 2021.
  • 34 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q3 2026, filed 29 Oct 2026.